The company manufactures active pharmaceutical ingredients (APIs) and intermediates using fermentation and chemical synthesis, primarily serving the pharmaceutical industry.
The company lacks a moat as evidenced by persistent, massive net losses (averaging -242% margin) and a total erosion of net worth. While they claim niche fermentation expertise, the inability to utilize capacity or generate positive gross margins contradicts any competitive advantage.
Capital allocation has been disastrous, characterized by chronic cash burn that has resulted in a deeply negative net worth (-16,275 lakhs). The company is entirely reliant on inter-corporate deposits and financial support from its promoter to remain a going concern.
The company's survival depended entirely on the life support of its promoter, Ipca Laboratories, which eventually ceased as the Vizag plant remained shuttered by environmental regulators. Without the ability to restart manufacturing or generate positive gross margins, the persistent cash burn finalized the erosion of all remaining assets. The legal disputes surrounding promoter shareholding and the lack of independent board oversight led to a total breakdown in governance, leaving minority shareholders with a worthless stake in a defunct shell company.
RichFakir rates Krebs Biochemicals & Industries Ltd's business quality as poor — 0/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
RichFakir's educational verdict on Krebs Biochemicals & Industries Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
View the full live analysis →